Introduction:
As potent antiretroviral therapy (ART) has markedly improved survival of persons with HIV (PWH) [1], chronic age-related diseases have emerged as predominant causes of death among ART-treated persons [2] . These conditions disproportionally affect aging PWH and include cardiovascular disease (CVD), metabolic diseases, and bone demineralization [3] [4] [5] .
Further compromising health among aging PWH is frailty, a syndrome of dysregulation of multiple biologic systems that leads to physical weakness and functional decline. Frailty prevalence increases with age after age 65 in the general population [6] , however it has been observed to occur up to a decade earlier among PWH [7] and is associated with excess burden of mortality and morbidity [8] . The frailty phenotype is a constellation of age-related symptoms that is associated with multiple adverse health consequences; previous studies have demonstrated an association between frailty and risk of poor health outcomes among PWH (such as neurocognitive impairment, falls, and disability) [9] [10] [11] , however the role of frailty as a predictor for subsequent development of specific age-related chronic diseases in this population is poorly understood. In this report, we sought to ascertain associations between baseline frailty and changes in frailty over 48 weeks with clinical outcomes including mortality, incident CVD, diabetes mellitus (DM) and bone disease. We postulated that frailty is positively associated with the occurrence of non-fatal disease-specific clinical events and mortality, and may therefore serve as a clinical predictor for these events.
Methods:
Study population:
AIDS Clinical Trials Group (ACTG) A5322 (HAILO: The HIV Infection, Aging, Immune Function Long-Term Observational Study) is an ongoing, observational study of 1035 older PWH (age ≥40 years at enrollment) that longitudinally evaluates associations between antiretroviral therapy, aging and inflammation with incidence of non-AIDS clinical events, mortality and functional status. Participants were recruited from a previous United States longitudinal cohort, ACTG Longitudinal Linked Randomized Trials (ALLRT), which enrolled participants between 2000 and 2007 who were followed through 2013 [12] . HAILO participants were enrolled in 2013-2014; the 1016 participants who had a baseline frailty assessment are included in this analysis. Study visits for HAILO participants occur semiannually with medication review, chart abstractions, plasma/serum collection, fasting laboratory tests, and falls interview. Frailty assessments, body measurements, neurocognitive evaluations, additional specimen collection, and questionnaires regarding substance use, sexual behavior, insurance status and Instrumental Activities of Daily Living (IADLs) are performed annually.
Frailty assessment:
Frailty was assessed among all participants using the Fried's frailty assessment [6] . As previously described, the assessment includes the 5 components of weak grip, slow gait speed on a 4-meter walk, and self-reported weight loss, exhaustion, and limitations in ability to undertake vigorous physical activity [13] . Frailty at baseline (time of HAILO entry visit) was evaluated, and participants were categorized as frail if they met 3-5 criteria, pre-frail if they met 1-2 criteria, or non-frail if they did not meet any criteria. Change in frailty was defined as ≥1 component increase in frailty (versus no change or a decrease in frailty; separate assessment of decrease in frailty was not possible due to small numbers) from baseline to week 48.
Clinical outcomes:
We included clinical events that occurred after the baseline frailty assessment.
Individuals with prevalent disease (any history of a diagnosis prior to baseline) with the exception of bone disease (for this outcome, history of bone disease was evaluated as a potential confounder) were excluded. CVD included coronary artery disease (with or without revascularization surgery), myocardial infarction, stroke/transient ischemic attack, angina, peripheral arterial disease, cardiomyopathy/heart failure, arrhythmia, deep vein thrombosis, and pulmonary embolism. Diabetes was defined as use of diabetic medication, hemoglobin A1c ≥6.5%, or a medical diagnosis of diabetes, and bone disease included fracture, avascular necrosis, osteopenia, or osteoporosis. Mortality was defined as death due to any cause.
Demographic, behavioral and clinical factors considered as confounders:
All covariates were assessed at baseline unless otherwise indicated. Race/ethnicity was categorized as black (non-Hispanic), white (non-Hispanic), Hispanic/other, age as 40-49, 50-59, and ≥60 years, sex as male or female. Education level was categorized as "did not complete high school", "completed high school", or "completed education beyond high school". Self-reported smoking was categorized as "never smoker", "former smoker", or "current smoker". Alcohol use assessment included a categorical variable for binge drinking (≥5 drinks for men, ≥4 for women within a 2-hour period), categorized as "no drinking", "no binging drinking", "binge drinking once/month", and "binge drinking more than once/month". A separate variable for self-reported frequency of alcohol use was categorized as "no drinking", "light/moderate drinking" (1-14 drinks/week for men, 1-7 drinks/week for women, and no binge drinking), or "heavy drinking" (>14 drinks/week for men, >7 drinks/week for women, or binge drinking). Physical activity was defined as ≥ 3 days of moderate or vigorous activity per week. Body mass index (BMI) was categorized as underweight (BMI: <18.5 kg/m 2 ), normal (BMI: 18.5 -<25 kg/m 2 ), overweight (BMI: 25-30 kg/m 2 ), and obese (BMI: >30 kg/m 2 ). Waist circumference was categorized as low (≤94cm for men, ≤80cm for women), high (>94cm for men, >80cm for women), or unknown. AIDS-defining events, liver disease, renal disease, bone disease, diabetes, family history of CVD, family history of diabetes, and depression were also considered as potential confounders for specific outcomes.
Statistical Analysis:
For each clinical outcome, we calculated overall rates per 100 person-years and their 95% confidence intervals using exact Poisson confidence limits. Follow-up time was time from baseline to date of the most recent visit, last clinic date for off-study participants, or date of clinical outcome, whichever occurred first.
Separate Poisson regression models were used to estimate the associations between frailty and each clinical outcome. For each frailty-outcome model, we made the a priori decision to force variables into the model that are known strong risk factors for the outcome (Figure 1 ).
We then proceeded to assess other covariates as potential confounders. Each covariate was added individually into the model including frailty and the variables that were included a priori.
Covariates that changed the effect estimate by ≥10% were kept in the final multivariable model.
After fitting the final multivariable model for baseline frailty and the clinical outcome, we replaced frailty with (a) grip and (b) walk speed.
The same model-building procedures were used to evaluate the association between frailty change from baseline to week 48 and each clinical outcome. For this evaluation, we included clinical events that occurred after the second frailty assessment at week 48. All participants lost to follow up or who experienced the clinical outcome before week 48 were excluded (with the exception of bone disease, where history of bone disease prior to week 48 was evaluated as a potential confounder). While physical activity at baseline was not included as a potential confounder in any of the evaluations of baseline frailty and clinical outcomes (since frailty at baseline may be affected by physical activity), baseline physical activity was evaluated as a potential confounder when evaluating change in frailty from baseline to week 48.
We also summarized the time to event in months for each outcome to examine whether any outcomes occurred close to the time of the frailty assessment.
Results:
Among 821 men and 195 women, 48% were white, non-Hispanic and 46% were between 40-49 years of age at study entry. The majority (926, 91%) were virally suppressed (HIV RNA <50 copies/mL) at baseline with a median baseline CD4 of 621 cell/µL. With the exception of seven participants, all were taking antiretroviral therapy upon study entry (five of those seven started antiretroviral therapy after study entry). Participant demographic and clinical characteristics are shown in Table 1 . At baseline, 390 (38%) were pre-frail and 62 (6%) frail.
Frailty scores increased in one or more components among 194 (19%) participants from baseline to 48 weeks; among these participants, increases in the following frailty components were An increase in frailty from baseline to week 48 was significantly associated with mortality (IRR 3.78 [1.52-9.39], p=0.004), but was not associated with incident CVD, diabetes, or bone events ( Table 2) . Baseline pre-frailty was not significantly associated with any of the clinical outcomes.
Discussion
In this large, well-characterized cohort of PWH, the vast majority of whom were virally suppressed with CD4 count >600 cells/µL, the presence of frailty at study entry was associated with greater risk for subsequent incident CVD, diabetes, and bone disease independent of traditional risk factors for such diseases, while increase in frailty over 48 weeks was associated with increased risk for death. Furthermore, the objective frailty component of slow gait, a strong predictor of mortality among older adults without HIV [14] , was associated with incident diabetes and CVD (borderline), but not with mortality or bone disease event. These observations illustrate an intimate relationship between frailty, a marker of vulnerability and physiologic dysregulation, with the development of age-related chronic diseases and death among middleaged and older PWH.
The occurrence of the frailty phenotype prior to clinical disease onset suggests that frailty is associated with the development of these chronic diseases in our cohort. The detrimental impact of frailty on many subsequent poor health outcomes (including falls, hospitalization, disability, and mortality) has been well-described among both PWH and in the general population [9] [10] [11] [15] [16] [17] [18] [19] [20] [21] [22] . Increases in frailty score have also been shown to be associated with increased mortality risk in the general population [23] , so our observed mortality association is not unexpected. Nonetheless, since PWH have a higher prevalence of frailty and progress to frailty faster than persons in the general population [7, 24] , our observation underscores a potentially greater risk of mortality consequent to frailty among PWH.
Prior studies evaluating associations between frailty and risk of chronic diseases, however, have reported variable results. Among the general population, frailty (as well as prefrailty) has been found to be independently associated with an increased risk of CVD [25, 26] , with slow gait speed, or variations of it, also associated with this increased risk [26, 27] . In the Multicenter AIDS Cohort Study (MACS), frailty was associated with subclinical atherosclerosis in men without HIV but not PWH. An association between higher frailty score and CVD was suggested in a prior cross-sectional analysis of our cohort [13] , however this association was not statistically significant in the final multivariable model. In this current, prospective analysis, the association between baseline frailty and risk of incident CVD, as well as the borderline association between slow gait speed and risk of incident CVD, among PWH appears to increasingly corroborate findings observed in the general population.
The association between frailty and DM is less clear. Insulin resistance and/or DM have been identified as an antecedent to frailty among elderly persons without HIV as well as PWH, but not vice versa [28] [29] [30] . Our current finding of frailty (and specifically slow gait speed) as an independent risk for incident DM presents an opposing sequence of events, further underscoring the multifarious relationship of frailty to age-related changes in physiologic processes. Frailty as a predictor of fracture, conversely, has also been widely demonstrated in the general population and PWH [20, 31, 32] , and our findings are consonant with these associations. Despite the low number of clinical events and relatively low prevalence of frailty (6%) in our cohort, the significant impact of frailty on risk of several chronic diseases and mortality within a single cohort is noteworthy. Further, our cohort has a high rate of durable viral suppression, which While our findings suggest that baseline frailty can precede certain chronic diseases among PWH, they do not establish a causal pathway between frailty and chronic disease development. Pathophysiologic mechanisms may exist, however, that are common to both.
Similar to the widely-studied associations between chronic immune activation and inflammation as contributors to specific chronic diseases among PWH, elevations in levels of multiple systemic markers of inflammation have been associated with the development of frailty among PWH [33] [34] [35] [36] [37] . Indeed, levels of specific markers of inflammation associated with CVD among PWH, such as interleukin-6 (IL-6), high sensitivity C-reactive protein (hsCRP), sCD14 and sCD163 have been independently associated with frailty [33, 35, [37] [38] [39] [40] . Inflammation associated with frailty and age-related chronic disease may be particularly relevant to PWH, since increased inflammation is fundamental to HIV pathophysiology. Additionally, accelerated sarcopenia and adiposity can occur in the setting of HIV [41] , which may consequently contribute to sedentary lifestyle, thereby hastening metabolic derangements (such as insulin resistance) and contributing to chronic disease development. Functional impairments characteristic of frailty can further compound this process. These are especially important considerations in risk stratification for certain diseases, as traditional screening tools, such as the American College of Cardiology/American Heart Association (ACC/AHA) pooled cohort equation and the FRAX score, under-predict disease-specific clinical events for PWH [42, 43] .
Our findings support the utility of frailty assessments in the standard health maintenance of aging PWH. This may serve as a simple yet high-impact predictor of chronic, age-related diseases and better inform current predictive risk models, however further investigation is needed to determine optimal strategies to incorporate use of frailty scores in chronic disease risk stratification. Once identified, frailty development may be halted or reduced by physical activity training; such progams have been shown to increase strength, balance and physical activity among elderly HIV-negative participants, ultimately leading to reduction in frailty [44] [45] [46] . For aging PWH, structured exercise programs have been shown to improve weight, strength, and cardiorespiratory fitness, and even reduce the number of frailty criteria [47, 48] . Such interventions are low-risk and, at minimum, may improve health outcomes directly consequent to frailty.
Limitations to our work exist. While our median age of 51 is consistent with the median age of PWH in the United States, our outcomes may not be generalizable to younger PWH. The majority of HAILO participants are durably virally suppressed and compliant with healthcare and research participation. Our study results may therefore not be generalizable to individuals with intermittent virologic non-suppression or gaps in care. We observed a small number of deaths relative to the other outcomes in our study, therefore our analysis may have been underpowered for the mortality outcome. In our final regression models, we adjusted for covariates known to be traditionally strong risk factors for each outcome of interest. It is possible, however, that there exist other risk factors we did not consider, which may have resulted in unmeasured confounding. Further, the self-reported nature of smoking and other substance use, as well as family history of specific diseases, may have led to underrerporting of these entities. Three components of the frailty evaluation (weight loss, exhaustion and low In summary, we found that the presence of frailty and increases in frailty scores over time among treated, virally-suppressed PWH preceded multiple chronic disease-specific events and mortality. Routine incorporation of annual frailty assessments in the care of PWH (perhaps beginning as early as the sixth decade of life) can enhance the characterization of age-related functional declines, and may thereby aid in risk stratification for the development of ageassociated chronic diseases. Further, frailty may comprise a modifiable target for interventions aimed at improvement of functional status and, potentially, co-morbidity avoidance. 
